Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Sep;120(3):378-382.
doi: 10.1016/j.radonc.2016.02.010. Epub 2016 Feb 17.

Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial

Ludy C H W Lutgens  1 , Peter C M Koper  2 , Jan J Jobsen  3 , Elzbieta M van der Steen-Banasik  4 , Carien L Creutzberg  5 , Hetty A van den Berg  6 , Petronella B Ottevanger  7 , Gerard C van Rhoon  8 , Helena C van Doorn  9 , Ruud Houben  10 , Jacoba van der Zee  8
Affiliations
Clinical Trial

Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial

Ludy C H W Lutgens et al. Radiother Oncol. 2016 Sep.

Abstract

Background: Chemoradiation (RT-CT) is standard treatment for locally advanced cervical cancer (LACC). This study tried to establish if radiotherapy combined with hyperthermia (RT-HT) should be preferred in bulky and/or FIGO-stage ⩾III.

Methods: In this open-label, multicenter randomized trial, patients with LACC were randomly assigned by a computer-generated, biased coin minimization technique to RT-CT or RT-HT. Central randomization was done with stratification by FIGO-stage, tumour diameter and nodal status. Primary endpoint was event free survival (EFS). Secondary endpoints were pelvic recurrence free survival (PRFS), overall survival (OS) and treatment related toxicity. Analysis was done by intention to treat.

Results: The trial was closed prematurely (87 of 376 planned patients enrolled: 43 RT-CT; 44 RT-HT). Median follow-up time was 7.1 years. The cumulative incidence of an event was 33% in the RT-CT group and 35% in the RT-HT group. The corresponding hazard rate (HR) for EFS was 1.15 (CI: 0.56-2.36, p=0.7). Also the hazards for PRFS (0.94; CI 0.36-2.44) and OS (1.04; CI 0.48-2.23) at 5 years were comparable between both treatment arms as was grade ⩾3 radiation related late toxicity (6 RT-CT and 5 RT-HT patients).

Conclusion: After 25% of intended accrual, data suggest comparable outcome for RT-CT and RT-HT.

Keywords: Cervical cancer; Concurrent chemoradiation; Regional hyperthermia.

PubMed Disclaimer